Loading
NI
NantHealth, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SOON-SHIONG PATRICK, was filed 30 Aug 2023.
NantHealth, Inc.: what insiders have been doing
Every trade that managers of NantHealth, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Nothing new has been filed by managers of NantHealth, Inc. in twelve months, the latest record being from 30 August 2023.
Our records for NantHealth, Inc. go back to 2016, with 5 purchases and 19 sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
85
Thresholds
n/a
Buy Volume
€32M
5 ops. · all time
Sell Volume
€611,650
19 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$57.7M
Gross profitUS$32.9M57% margin
Net income-US$58.4M-101.2% margin
Last declaration on 30 August 2023
Declarations85 total
537,272 shares@ US$18.6125Common StockSEC:0000950170-23-045521:1
Canonical exit: 26 Nov 2023 (T+90)
15,384,616 shares@ US$0.39100.0% of flowCommon StockSEC:0000950170-23-045521:0
Canonical exit: 26 Nov 2023 (T+90)
7,320 shares@ US$2.05491.1% of flowCommon StockSEC:0000899243-21-035924:1
9,200 shares@ US$0.55010.4% of flowCommon StockSEC:0000899243-21-035924:2
9,200 shares@ US$1.96081.3% of flowCommon StockSEC:0000899243-21-035924:3
7,320 shares@ US$0.550183.0% of flowCommon StockSEC:0000899243-21-035924:0
1,505 shares@ US$2.33540.2% of flowCommon StockSEC:0000899243-21-035503:1
16,613 shares@ US$0.55010.6% of flowCommon StockSEC:0000899243-21-035503:2
16,613 shares@ US$2.29632.7% of flowCommon StockSEC:0000899243-21-035503:3
4,700 shares@ US$0.55010.2% of flowCommon StockSEC:0000899243-21-035503:4
4,700 shares@ US$2.25160.7% of flowCommon StockSEC:0000899243-21-035503:5
1,505 shares@ US$0.550117.0% of flowCommon StockSEC:0000899243-21-035503:0
1,689,189 shares@ US$2.9629.6% of flowCommon StockSEC:0000899243-21-015976:0
Canonical exit: 12 Jul 2021 (T+90)
80,000 shares@ US$3.7120.5% of flowCommon StockSEC:0000899243-21-012028:0
55,962 shares@ US$2.8197.2% of flowCommon StockSEC:0000899243-20-012104:1
125,195 sharesCommon StockSEC:0000899243-20-012104:0
179,558 shares0Common StockSEC:0000899243-20-008306:0
5,000,000 shares0Common StockSEC:0000899243-19-026921:0
125,196 sharesCommon StockSEC:0000899243-19-012058:0
55,964 shares@ US$0.7147.8% of flowCommon StockSEC:0000899243-19-012058:1
10,000 sharesCommon StockSEC:0000899243-18-026470:0
3,696 shares@ US$1.420.5% of flowCommon StockSEC:0000899243-18-026470:1
6,304 shares@ US$1.420.9% of flowCommon StockSEC:0000899243-18-026470:2
45,002 shares0Common StockSEC:0000899243-18-024014:0
52,910 shares0Common StockSEC:0000899243-18-024014:1
25 of 85 declarations
About NantHealth, Inc.
NantHealth, Inc. is a US-listed healthcare technology company historically traded on the NASDAQ (NASDAQ-GS: NH). The company is based in Morrisville, North Carolina, United States, and operates at the intersection of digital healthcare, precision medicine, and payer-provider workflow automation. Its business model is centered on software and SaaS-based solutions sold to health plans, providers, hospitals, and related healthcare organizations.
Founded in July 2010, NantHealth emerged from the NantWorks ecosystem with an early vision of combining clinical data, analytics, and interoperability to support more personalized care. Over time, the company has narrowed and sharpened its portfolio around a few core platforms. The best-known product is NaviNet, a payer-provider collaboration network used to support eligibility and benefits, prior authorization, document exchange, referrals, and other administrative workflows. Another core offering is Eviti, an oncology decision-support and treatment validation platform designed to help align care pathways with evidence-based protocols and coverage requirements. NantHealth has also offered data and analytics services, historically including Quadris and related professional services. In addition, the company acquired OpenNMS, an open-source network management platform, which expanded NantHealth’s software footprint beyond healthcare and reinforced its cloud, SaaS, and AI capabilities.
Read moreShow less
From a competitive standpoint, NantHealth operates in a fragmented but demanding market where differentiation depends on interoperability, data security, regulatory compliance, and the ability to reduce administrative friction across the care continuum. The company positions itself as a bridge between complex healthcare data and actionable decision-making, with a focus on helping stakeholders automate processes, improve visibility, and support better patient outcomes. Its customer base is primarily US-centric, although the company has also maintained offices and team presence in locations such as Belfast, Northern Ireland, and other US sites.
Recent developments have emphasized product execution and platform monetization. In 2025, NantHealth introduced enhanced NaviNet AllPayer offerings with electronic claim submission functionality, expanding the platform’s value proposition for provider practices and payers. The company has also highlighted ongoing product updates, customer adoption efforts, and continued investment in automation and artificial intelligence. Earlier strategic actions, including asset sales and financing transactions, reflect a broader effort to simplify the portfolio and support liquidity. For investors, NantHealth remains a relatively small-cap US healthcare technology name, with a specialized product set and a risk profile that can be more volatile than that of larger healthcare IT peers.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
